CD8A and neoplasm: This therapy activates the specific and non-specific immune response against vessels and tumor cells, inhibits angiogenesis, reduces the M2 phenotype of TAMs, induces the recruitment of CD8+ and CD4+ lymphocytes, and inhibits primary tumor growth and metastases.